By Kim Han-joo
SEOUL, Dec. 19 (Yonhap) -- South Korean drugmaker Daewoong Pharmaceutical Co. said Thursday it has won approval from authorities in the United Arab Emirates (UAE) and Indonesia for the sale of its botulinum toxin product.
The Ministry of Health in the UAE and Indonesia's Badan Pengawas Obat dan Makanan accepted Daewoong Pharmaceutical's application to sell Nabota.
The product is South Korea's first botulinum toxin product to receive the green light for the treatment of frown lines.
With the approval, Nabota can be sold in the two countries during the first half of next year, the company said.
Daewoong Pharmaceutical said its UAE partner, Dansys Group, will be in charge of the sales of Nabota in the Middle Eastern country.
A marketing partner for Indonesia has not yet been decided, the company officials said.
"The approval will help Daewoong Pharmaceutical make further inroads into the Middle Eastern botulinum toxin market, since the UAE serves as a hub," Park Seong-soo, a company official, said.
Indonesia is one of the world's fastest-growing beauty markets as the country boasts the fourth-largest population, according to the company official.
The product has already won approvals from authorities in the United States and the European Union.
BTS to appear on Korean TV shows this month
(LEAD) 2 patients die after AstraZeneca vaccine shots; study under way over potential connection
Three more die after receiving AstraZeneca vaccine
J-Hope releases new song 'Blue Side' on 'Hope World' anniversary
'Please Look After Mom' author vows to 'write on' following plagiarism row
Couple indicted on murder charge over fatal abuse of 10-year-old niece
85,000 foreign workers in Gyeonggi ordered to take COVID-19 test before March 22
S. Korea tentatively concludes no link between COVID-19 vaccination and deaths
Another delivery worker dies from apparent overwork
(LEAD) S. Korea, U.S. reach defense cost-sharing agreement